Evidence
This page contains a snapshot of featured content which highlights evidence addressing key clinical questions including areas of uncertainty. Please see the main topic reference list for details of all sources underpinning this topic.
Cochrane Clinical Answers
Cochrane Clinical Answers (CCAs) provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane systematic reviews. They are designed to be actionable and to inform decision making at the point of care and have been added to relevant sections of the main Best Practice text.
- What are the effects of pregabalin add‐on for people with drug‐resistant focal epilepsy?
- For adults with drug‐resistant focal epilepsy, what are the effects of adjunct eslicarbazepine acetate?
- What are the effects of rufinamide as an adjunct to conventional antiepileptic drug (AED) therapy for people with refractory epilepsy?
- What are the effects of tiagabine add‐on therapy for people with drug‐resistant focal epilepsy?
- How does vigabatrin add‐on therapy compare with placebo for adults and adolescents with drug‐resistant focal epilepsy?
- Do psychological treatments improve quality of life for people with epilepsy?
- For people with drug‐resistant epilepsy, how do different ketogenic diets compare?
- What are the effects of a ketogenic diet for people with drug‐resistant epilepsy?
- What are the effects of rufinamide as an adjunct to conventional antiepileptic drug (AED) therapy for people with refractory epilepsy?
- What are the benefits and harms of losigamone add‐on therapy for adults with focal epilepsy?
Use of this content is subject to our disclaimer